Symdeko: An Overview of Uses, Dosage, Demographics, Side Effects, Interactions, and Generic Options Symdeko is a medication used in the treatment of cystic fibrosis (CF) in patients aged 12 years and above who have specific genetic mutations in their CF transmembrane conductance regulator (CFTR) gene. It is approved by the U.S. Food and Drug Administration (FDA) and is available through prescription only. Uses: Symdeko is used to improve lung function in CF patients with specific genetic mutations. It works by improving the function of the CFTR protein, which helps to decrease the viscosity of mucus in the lungs and other organs. This, in turn, leads to improved clearance of mucus and reduction of symptoms such as cough, shortness of breath, and respiratory infections. Dosage: Symdeko is available in tablet form and is to be taken orally twice a day, with or without food. The recommended dosage is one tablet of 100mg tezacaftor and 150mg ivacaftor taken in the morning and one tablet of 100mg tezacaftor and 75mg ivacaftor taken in the evening. The tablets should be swallowed whole and not crushed, chewed, or broken. Demographics: Symdeko is approved for use in patients aged 12 years and above who have specific genetic mutations in their CFTR gene. The specific mutations include F508del mutation in the CFTR gene, which is the most common genetic mutation in CF patients. Symdeko is not recommended in patients with severe hepatic impairment and those who are allergic to any of its ingredients. Side Effects: The most common side effects of Symdeko include headache, nausea, diarrhea, respiratory infections, and rash. Other potential side effects include elevated liver function tests, dizziness, chest tightness, and hypoglycemia. If you experience any adverse effects, contact your healthcare provider. Interactions: Symdeko may interact with several medications, including strong CYP3A inhibitors such as ketoconazole, itraconazole, and clarithromycin, which may increase the level of ivacaftor in the blood. This can lead to increased risk of side effects such as elevated liver function tests, dizziness, or nausea. Patients should inform their healthcare provider of all medications they are taking before starting Symdeko treatment. Generic Options: Symdeko is a combination of two drugs, tezacaftor and ivacaftor, and is not available in generic form. However, generic versions of ivacaftor are available in the market under the name Kalydeco. Tezacaftor is only available in combination with ivacaftor under the trade name Symdeko. In conclusion, Symdeko is a medication approved by the FDA for use in CF patients aged 12 years and above with specific genetic mutations. It improves lung function and reduces respiratory symptoms in CF patients by facilitating optimal functioning of the CFTR protein. Although it may cause mild side effects, it is generally well-tolerated by most patients. Symdeko is not available in generic form, but generic versions of ivacaftor are available.